Clinical Trials

Status
Title Sort descending Intervention Sponsor Status
Obeticholic Acid for Prevention in Barrett's Esophagus Biospecimen Collection, Esophageal Biopsy, Esophagogastroduodenoscopy, Liver Ultrasonographic Elastography, Obeticholic Acid, Placebo Administration, Questionnaire Administration National Cancer Institute (NCI) Recruiting
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study Lisinopril, Questionnaire Administration, Biospecimen Collection, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction National Cancer Institute (NCI) Recruiting
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis Questionnaire Administration, Simvastatin, Placebo Administration, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging National Cancer Institute (NCI) Active, not recruiting
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration National Cancer Institute (NCI) Recruiting
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration National Cancer Institute (NCI) Recruiting
Testing Obeticholic Acid for Familial Adenomatous Polyposis Biopsy, Obeticholic Acid, Placebo Administration, Biospecimen Collection, Gastrointestinal Endoscopy, Questionnaire Administration National Cancer Institute (NCI) Recruiting
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) Placebo, Sulindac 400 MG Duke University Recruiting
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline National Cancer Institute (NCI) Active, not recruiting